Among adults with relapsed or refractory indolent B-cell non-Hodgkin lymphoma, the phase 2 TRANSCEND FL trial met its primary ...

China's National Medical Products Administration has approved a Phase III trial of InnoCare Pharma’s ICP-248 (Mesutoclax) ...

Imbruvica (ibrutinib) is a Bruton’s tyrosine kinase (BTK) inhibitor approved for the treatment of Small Lymphocytic Lymphoma (SLL). It works by blocking BTK, a critical enzyme in B-cell receptor ...

Brice and Amanda Dieter of Jamestown had their figurative worlds upended in October 2023. It was at this time that the ...

A cancer is cured when there are no signs of cancer ... It starts in one of the testicles (testes), the small organs located in the scrotum. They produce the hormone testosterone, as well as ...

The addition of epcoritamab-bysp to standard chemotherapy significantly improved response and survival for patients with ...

The FDA has approved Adcetris (brentuximab vedotin) for use in combination with lenalidomide and rituximab to treat patients with relapsed/refractory LBCL after 2 or more lines of systemic therapy who ...

More than 13 years after its initial FDA approval, Pfizer’s blood cancer drug Adcetris has nabbed another regulatory green ...

The FDA has approved a new three-drug combination to treat certain types of an aggressive blood cancer called large B-cell lymphoma (LBCL).

Combination Targeted Treatment Produces Lasting Remissions in People With Resistant Aggressive B-Cell Lymphoma June 19, 2024 — Researchers have developed a non-chemotherapy treatment regimen ...